Fig. 3From: Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is nowComparison of pathologic complete response rate between neoadjuvant chemotherapy regimens from different clinical studies (T, taxanes; H, trastuzumab; P, pertuzumab; L, lapatinib; Cb, carboplatin; F, fluorouracil; E, epirubicin; Py, pyrotinib; Chemo, chemotherapy)Back to article page